Getz Healthcare Australia has announced a strategic distribution agreement with IGEA Medical to introduce the Cliniporator VITAE, an advanced reversible electroporation technology, to Australian healthcare providers. Following its successful launch in New Zealand, this partnership marks a significant milestone in expanding innovative cancer and vascular malformation treatment options throughout the region.

The Cliniporator VITAE, developed by IGEA Medical, represents a breakthrough in tissue electroporation. Utilising adaptive reversible electroporation technology, it delivers precise electrical pulses that enhance the uptake of chemotherapy agents into cancer cells. This minimally invasive, highly targeted approach provides a new frontier in cancer care and vascular malformation treatment, offering clinicians cutting-edge technology to improve patient outcomes.

This agreement reinforces Getz Healthcare's commitment to delivering the latest medical innovations. By introducing the Cliniporator VITAE, Getz Healthcare empowers clinicians with advanced solutions that enhance patient care and create new possibilities for therapeutic innovation.

Derek Foltin, Managing Director at Getz Healthcare Australia & New Zealand said, "This collaboration represents a significant step forward in our mission to bring meaningful healthcare solutions to the people of Asia Pacific. By introducing this groundbreaking electroporation technology to Australian clinicians, we aim to elevate standards in cancer and vascular malformation treatments. We look forward to the positive impact this innovation will have on patient outcomes and to deepening our partnership with IGEA to drive further advancements across the region."